Bioskryb

BioSkryb Genomics delivers high-fidelity single-cell data that reveals biology at unprecedented resolution. The company patented whole genome amplification technology, primary template-directed amplification (PTA), achieves 97% genome coverage and is combined with full-length transcriptome and surface protein analysis from individual cells in a unified, single-day, automation-compatible workflow. This complete genotype-to-phenotype view enables breakthrough discoveries in research and therapeutic development, powers next-generation diagnostics, and generates clinical-grade datasets for AI-driven precision medicine. The product portfolio includes ResolveDNA for genome recovery above 95% with SNV calling sensitivity, ResolveOME for simultaneous genome and transcriptome amplification from the same cell eliminating sample splitting, and BaseJumper bioinformatics platform for identifying high-quality single-cell multiomic data for AI training models. The platform addresses the diagnostics quantity-not-sufficient crisis with femtogram-scale sensitivity, recovering data from up to 30% of QNS cases in high-volume workflows. Applications span oncology, neurology, measurable residual disease detection, FFPE multiomic solutions, and AI dataset partnerships. Founded in 2018 and headquartered in Durham, United States, BioSkryb has raised approximately 11.5 million at the Seed stage with investors including Anzu Partners and Wilson Sonsini Goodrich and Rosati.